CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|September 1, 2002
Diovan (Valsartan) Novartis
ARB now indicated for heart failure
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Christine Johnston on why biosimilars are losing formulary ground
2
Dan Nardi of Reimagine Care discusses how to help community practices scale CAR-T programs
3
Medicare Advantage needs fixing. Here are 3 feasible repairs
4
Closing the outpatient monitoring gap in cancer
5